BTK and glioblastoma: By contrast, our study demonstrated that although BTK is a dominant bioactive kinase within GBM tissue, neither patient-derived cancer stem-like cell lines nor SOX2-positive cancer cells within GBM tissue express detectable or high levels of BTK protein, that is, 12% of cells co-express SOX2 and BTK (Fig 10).